AstraZeneca PLC
AZN · NASDAQ
9/30/2025 | 6/30/2025 | 3/30/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $15,191 | $14,457 | $13,588 | $14,891 |
| % Growth | 5.1% | 6.4% | -8.8% | – |
| Cost of Goods Sold | $2,862 | $2,473 | $2,241 | $2,725 |
| Gross Profit | $12,329 | $11,984 | $11,347 | $12,166 |
| % Margin | 81.2% | 82.9% | 83.5% | 81.7% |
| R&D Expenses | $3,663 | $3,548 | $3,159 | $4,677 |
| G&A Expenses | $4,972 | $4,864 | $4,492 | $5,410 |
| SG&A Expenses | $5,120 | $5,007 | $4,627 | $5,553 |
| Sales & Mktg Exp. | $148 | $143 | $135 | $143 |
| Other Operating Expenses | -$37 | -$79 | -$113 | -$100 |
| Operating Expenses | $8,746 | $8,476 | $7,673 | $10,130 |
| Operating Income | $3,583 | $3,508 | $3,674 | $2,036 |
| % Margin | 23.6% | 24.3% | 27% | 13.7% |
| Other Income/Exp. Net | -$339 | -$381 | -$272 | -$370 |
| Pre-Tax Income | $3,244 | $3,127 | $3,402 | $1,666 |
| Tax Expense | $709 | $679 | $481 | $166 |
| Net Income | $2,533 | $2,450 | $2,916 | $1,500 |
| % Margin | 16.7% | 16.9% | 21.5% | 10.1% |
| EPS | 0.82 | 0.79 | 0.94 | 0.49 |
| % Growth | 3.8% | -16% | 91.8% | – |
| EPS Diluted | 0.81 | 0.79 | 0.94 | 0.48 |
| Weighted Avg Shares Out | 3,127 | 3,100 | 3,100 | 3,100 |
| Weighted Avg Shares Out Dil | 3,122 | 3,118 | 3,122 | 3,124 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $68 | $84 | $64 |
| Interest Expense | $349 | $439 | $349 | $429 |
| Depreciation & Amortization | $1,549 | $1,389 | $1,284 | $714 |
| EBITDA | $5,142 | $4,955 | $5,035 | $2,809 |
| % Margin | 33.8% | 34.3% | 37.1% | 18.9% |